Skip to main content

Table 1 Characteristics of participants in this study

From: Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease

Aβ PET status Aβ− Aβ+ p value
341 participants with CSF Aβ40, Aβ42 and pTau, Aβ PET, and tau PET
 Sample size 195 (57%) 146 (43%)  
 CU/MCI/AD 145/46/4 74/45/27  
 Age (years) 70.4 (9.4) 74.7 (10.4) <  0.001
 Education (years) 18 (2) 16 (3) 0.07
 Female (%) 115 (59%) 78 (53%) 0.44
 APOE-ε4 (%) 37 (19%) 83 (57%) <  0.001
 Aβ PET (Centiloids) 4.9 (11.0) 71.2 (59.0) <  0.001
 CSF Aβ42 1421 (817) 653 (377) <  0.001
 CSF Aβ40 18,440 (7680) 17,770 (6150) 0.56
 CSF pTau 17.8 (8.2) 27.2 (19.9) <  0.001
 CSF pTau/Aβ40 0.0010 (0.0002) 0.0016 (0.0009) <  0.001
 FTP SUVR (Temporal-metaROI) 1.16 (0.08) 1.28 (0.27) <  0.001
 aHCV (mm3) 7530 (1469) 6990 (1750) <  0.001
 PACC 0.25 (5.06) −2.33 (11.64) <  0.001
116 participants with ≥ 2 tau PET scans
 Sample size 41 (35%) 75 (65%)  
 CU/MCI/AD 26/14/1 39/25/11  
 FTP visits (median (IQR, range), no.) 2.0 (1.0, 2–4) 2.0 (1.0, 2–4)  
 FTP follow-up (Median (IQR, range), years) 1.8 (1.1, 0.8–3.3) 1.2 (1.0, 0.7–3.1)  
139 participants with ≥ 2 aHCV data
 Sample size 64 (46%) 75 (54%)  
 CU/MCI/AD 42/20/2 39/24/12  
 MRI visits (median (IQR, range), no.) 2.0 (0, 2–4) 2.0 (0.5, 2–4)  
 MRI follow-up (median (IQR, range), years) 2.0 (1.0, 0.9–3.8) 1.2 (0.9, 0.8–3.2)  
202 participants with ≥ 2 PACC measurements
 Sample size 99 (49%) 103 (51%)  
 CU/MCI/AD 60/37/2 49/36/18  
 PACC visits (median (IQR, range), no.) 2 (0, 2–4) 2 (1, 2–5)  
 PACC follow-up (median (IQR, range), years) 2.0 (1.0, 0.9–3.0) 1.1 (1.0, 0.7–4.0)  
  1. Abbreviations: amyloid-β, AD Alzheimer’s disease, aHCV adjusted hippocampal volume, CU cognitively unimpaired, FTP 18F-flortaucipir, IQR interquartile range, MCI mild cognitive impairment, PACC Preclinical Alzheimer Cognitive Composite, pTau phosphorylated tau, SUVR standardized uptake value ratio